Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Savient re-evaluating prosaptide

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Savient is terminating a Phase II study of prosaptide in HIV patients with peripheral neuropathic pain, the firm says March 11. "Over the next few months," Savient will decide whether it "will pursue alternative analgesia indications, or further explore the potential of prosaptide to treat peripheral neuropathy in HIV/AIDS and other diseases." Savient said the trial was stopped due to a low probability for attaining statistical significance for the analgesia efficacy endpoint. Prosaptide reached Phase II for diabetic peripheral neuropathy, but Savient decided to focus on peripheral neuropathy associated with HIV/AIDS...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS002841

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel